tirzepatide labs Lab Test – Healthogenics Tirzepatide Dual Agonist (GLP-1/GIP) |

Why this matters BIG TIME: Dual opportunity unlocked Covers Type-2 Diabetes and Chronic Weight Management two of Indias fastest-growing therapy segments Patent expiry catalyst India patent expiry expected in March 2026, setting the stage for large-scale generic entry Affordability revolution Generic semaglutide could be up to 70% cheaper, dramatically improving patient access Branded for impact Sematrinity Diabetes care Noveltreat Weight management Ready-to-use innovation Weekly dosing via prefilled pens (0.25 mg to 2.4 mg) convenience + adherence First-wave advantage Early DCGI approval gives Sun Pharma a strong launch edge in a fiercely competitive GLP-1 race Macro tailwinds Rising obesity, diabetes prevalence & metabolic disorders = long-term demand visibility Strategic takeaway: This isnt just another generic launch its a strategic bet on the future of metabolic healthcare in India

If more than 4 days have passed, skip it and resume your regular schedule

Potential to encourage fatty tissue to be used as energy

Generally, semaglutide has a half-life of seven days

Non-significant results were primarily observed for pancreatitis, severe hypoglycemia, and serious adverse events (SAEs)